Biosergen advances BSG005 antifungal drug candidate trial
Biosergen is advancing its drug candidate BSG005, designed as a rescue treatment for patients with invasive fungal infections. The company has enrolled the first cohort in their phase Ib Proof-of-Concept trial, with 5 out of a total of 15 patients included so far. Biosergen’s CEO, Tine Olesen, came to BioStock's studio to discuss this milestone, the company’s financing and the next steps ahead.
00:00 Introduction
00:21 How many patients are affected?
00:59 Today's treatments
02:44 BSG005
03:27 First patient cohort enrolled
04:55 One patient recovered
07:05 When are the results expected?
07:38 Financing
07:49 Finding an additional partner
08:58 Regulatory advice
Subscribe and follow BioStock on:
YouTube https://bit.ly/Biostock
LinkedIn: / biostock
Facebook: / biostock.se
https://www.biostock.se/
#BioStock #LifeScience #Biosergen
About BioStock
BioStock is Scandinavia's leading digital news and analysis service, exclusively focusing on the Life Science sector. Our primary editorial office and tv-studio are found at Medicon Village in Lund, one of Sweden's foremost innovation clusters for life science companies.